136 related articles for article (PubMed ID: 25965488)
1. Chitosan-isoniazid conjugates: Synthesis, evaluation of tuberculostatic activity, biodegradability and toxicity.
Berezin AS; Skorik YA
Carbohydr Polym; 2015 Aug; 127():309-15. PubMed ID: 25965488
[TBL] [Abstract][Full Text] [Related]
2. Peptide conjugates of therapeutically used antitubercular isoniazid-design, synthesis and antimycobacterial effect.
Horváti K; Mezo G; Szabó N; Hudecz F; Bosze S
J Pept Sci; 2009 May; 15(5):385-91. PubMed ID: 19319854
[TBL] [Abstract][Full Text] [Related]
3. The Introduction of Hydrazone, Hydrazide, or Azepane Moieties to the Triterpenoid Core Enhances an Activity Against
Kazakova OB; Medvedeva NI; Smirnova IE; Lopatina TV; Veselovsky AV
Med Chem; 2021; 17(2):134-145. PubMed ID: 31939731
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitubercular activity of substituted novel pyrazoline derivatives.
Ali MA; Yar MS; Kumar M; Pandian GS
Nat Prod Res; 2007 Jun; 21(7):575-9. PubMed ID: 17613813
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and antimycobacterial property of PEG-bis(INH) conjugates.
Kakkar D; Tiwari AK; Chuttani K; Khanna A; Datta A; Singh H; Mishra AK
Chem Biol Drug Des; 2012 Aug; 80(2):245-53. PubMed ID: 22515497
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.
Hearn MJ; Cynamon MH
J Antimicrob Chemother; 2004 Feb; 53(2):185-91. PubMed ID: 14688045
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
8. Isonicotinoylhydrazone analogs of isoniazid: relationship between superoxide scavenging and tuberculostatic activities.
Georgieva N; Gadjeva V
Biochemistry (Mosc); 2002 May; 67(5):588-91. PubMed ID: 12059780
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro antimycobacterial activity of 3-substituted 5-hydroxy-5-trifluoro[chloro]methyl-4,5-dihydro-1H-1-(isonicotinoyl) pyrazoles.
Almeida da Silva PE; Ramos DF; Bonacorso HG; de la Iglesia AI; Oliveira MR; Coelho T; Navarini J; Morbidoni HR; Zanatta N; Martins MA
Int J Antimicrob Agents; 2008 Aug; 32(2):139-44. PubMed ID: 18571384
[TBL] [Abstract][Full Text] [Related]
10. Transferrin conjugates of antitubercular drug isoniazid: Synthesis and in vitro efficacy.
Sutar YB; Mali JK; Telvekar VN; Rajmani RS; Singh A
Eur J Med Chem; 2019 Dec; 183():111713. PubMed ID: 31557610
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
Hearn MJ; Cynamon MH
Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
[TBL] [Abstract][Full Text] [Related]
12. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis.
Sriram D; Yogeeswari P; Yelamanchili Priya D
Biomed Pharmacother; 2009 Jan; 63(1):36-9. PubMed ID: 18343086
[TBL] [Abstract][Full Text] [Related]
13. Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain.
Boechat N; Ferreira VF; Ferreira SB; de Lourdes G Ferreira M; de C da Silva F; Bastos MM; Dos S Costa M; Lourenço MC; Pinto AC; Krettli AU; Aguiar AC; Teixeira BM; da Silva NV; Martins PR; Bezerra FA; Camilo AL; da Silva GP; Costa CC
J Med Chem; 2011 Sep; 54(17):5988-99. PubMed ID: 21776985
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Delivery of Isoniazid in Nanogel-Loaded Chitosan Hybrid Microparticles for Inhalation.
Omar SM; Maziad NA; El-Tantawy NM
J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):78-87. PubMed ID: 30526251
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis.
Horváti K; Bacsa B; Kiss E; Gyulai G; Fodor K; Balka G; Rusvai M; Szabó E; Hudecz F; Bősze S
Bioconjug Chem; 2014 Dec; 25(12):2260-8. PubMed ID: 25394206
[TBL] [Abstract][Full Text] [Related]
17. New isoniazid derivatives with improved pharmaco-toxicological profile: Obtaining, characterization and biological evaluation.
Dragostin I; Dragostin OM; Samal SK; Dash S; Tatia R; Dragan M; Confederat L; Ghiciuc CM; Diculencu D; Lupușoru CE; Zamfir CL
Eur J Pharm Sci; 2019 Sep; 137():104974. PubMed ID: 31252051
[TBL] [Abstract][Full Text] [Related]
18. [The mechanism of action of isoniazid. A chemical model of activation].
Bernadou J; Nguyen M; Meunier B
Ann Pharm Fr; 2001 Sep; 59(5):331-7. PubMed ID: 11787427
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, molecular docking and anti-tubercular activity of Plumbagin-Isoniazid Analog and its β-cyclodextrin conjugate.
Dandawate P; Vemuri K; Venkateswara Swamy K; Khan EM; Sritharan M; Padhye S
Bioorg Med Chem Lett; 2014 Nov; 24(21):5070-5. PubMed ID: 25264074
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro antitubercular activity of some 1-[(4-sub)phenyl]-3-(4-{1-[(pyridine-4-carbonyl)hydrazono]ethyl}phenyl)thiourea.
Sriram D; Yogeeswari P; Madhu K
Bioorg Med Chem Lett; 2006 Feb; 16(4):876-8. PubMed ID: 16303302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
